Session » 2020 Pediatric Rheumatology Symposium

2:30PM-3:30PM

Abstract Number: 003

Implementing Treat to Target Approach in the Care of Juvenile Idiopathic Arthritis Across a Network of Pediatric Rheumatology Centers

2:30PM-3:30PM

Abstract Number: 004

Implications of Adopting the Newly Proposed Pediatric Rheumatology International Trials Organization (PRINTO) Classification Criteria for Juvenile Idiopathic Arthritis (JIA): Results from the Research in Arthritis in Canadian Children, Emphasizing Outcomes (ReACCh-Out) Cohort

2:30PM-3:30PM

Abstract Number: 001

WITHDRAWN

2:30PM-3:30PM

Abstract Number: 002

WITHDRAWN

5:10PM-5:40PM

Abstract Number: 013

A Preliminary Data-driven Anatomic Classification for Childhood Takayasu Arteritis (cTA)

5:10PM-5:40PM

Abstract Number: 024

Abatacept Treatment Reduces Cutaneous and Joint Activity in Juvenile Localized Scleroderma

5:10PM-5:40PM

Abstract Number: 022

Association of Plasma Metabolomic Profiles with Methotrexate Response in Juvenile Idiopathic Arthritis

5:10PM-5:40PM

Abstract Number: 023

Capturing the Range of Disease Involvement in Localized Scleroderma: The Total Morbidity Score

5:10PM-5:40PM

Abstract Number: 019

Characterization of DOCK8 as a Novel Gene Associated with Cytokine Storm Syndrome

5:10PM-5:40PM

Abstract Number: 011

Chronic Non-bacterial Osteomyelitis (CNO): Correlation Between Clinical and Radiological Findings

5:10PM-5:40PM

Abstract Number: 018

Functional Characterization of PLCG2 Mutations Found in Subjects with Autoinflammation and PLCG2-Associated Antibody Deficiency and Immune Dysregulation (APLAID) Reveals Both Hypermorphic and Hypomorphic Mutants

5:10PM-5:40PM

Abstract Number: 016

Genetic Susceptibility Loci for Periodic Fever, Aphthous Stomatitis, Pharyngitis and Cervical Adenitis (PFAPA) Syndrome

5:10PM-5:40PM

Abstract Number: 025

HLA Genetic Signatures Associated with Inflammatory Sub-type in Juvenile Localized Scleroderma

5:10PM-5:40PM

Abstract Number: 020

Murine Roseolovirus Induces Autoimmune Disease and Development of Autoantibodies

5:10PM-5:40PM

Abstract Number: 017

MyD88 S209R-Mediated Immune Dysregulation in Mouse Models of Arthritis

5:10PM-5:40PM

Abstract Number: 021

Myositis Autoantibodies in a Racially Diverse Population of Children with Idiopathic Inflammatory Myopathies

5:10PM-5:40PM

Abstract Number: 015

Normal MRI Appearance of Marrow Adjacent to the Sacroiliac Joints in Healthy Children During Development

5:10PM-5:40PM

Abstract Number: 012

Pediatric Antiphospholipid Syndrome: Clinical Features and Therapeutic Interventions in a Series of 22 Cases

5:10PM-5:40PM

Abstract Number: 014

Successful Validation of a Rapid Point-of-care Test for Serum Calprotectin (MRP8/14) as Biomarker in Juvenile Idiopathic Arthritis

6:00PM-7:00PM

Abstract Number: 053

Acceptability and Usability Testing of a Preliminary Version of the JIA Option Map, an Electronic Decision Aid for Pain Management Options in Juvenile Idiopathic Arthritis

6:00PM-7:00PM

Abstract Number: 169

Addressing the Pediatric Rheumatology Workforce Shortage: Is Early Exposure Enough?

6:00PM-7:00PM

Abstract Number: 072

Allogenic Hematopoietic Stem Cell Transplantation for Refractory Childhood Rheumatic Diseases

6:00PM-7:00PM

Abstract Number: 041

Ancestry, Demographic and Clinical Features of Israeli Periodic Fever Aphthous Stomatitis, Pharyngitis and Adenitis (PFAPA) Syndrome – a Multi-center Cohort

6:00PM-7:00PM

Abstract Number: 066

Baseline Kidney Biopsy in Lupus Patients Without Renal Manifestations. Underappreciated or Overrated?

6:00PM-7:00PM

Abstract Number: 059

Challenges Faced by Families of Children with an Auto-inflammatory Disease

6:00PM-7:00PM

Abstract Number: 054

Clinical and Laboratory Characteristics in Juvenile-onset Systemic Lupus Erythematosus Across Age Groups

6:00PM-7:00PM

Abstract Number: 170

Clinical Team Perspectives on the Transition from Pediatric to Adult Care for Patients with Childhood-Onset SLE

6:00PM-7:00PM

Abstract Number: 171

Development and Acceptability of an Adolescent Self-management Program for Juvenile Idiopathic Arthritis

6:00PM-7:00PM

Abstract Number: 068

Development of CARRA Consensus Treatment Plans for Severe ANCA-associated Vasculitis – Final CARRA-wide Consensus

6:00PM-7:00PM

Abstract Number: 151

Differences in Chromatin Architecture Between Treatment-Naïve Pediatric and Adult Lupus Patients

6:00PM-7:00PM

Abstract Number: 073

Differences in Clinical Presentation Between Israeli and United States Children with Juvenile Spondyloarthritis

6:00PM-7:00PM

Abstract Number: 055

Differential Analysis of Serum and Urine S100 Proteins in Juvenile-onset Systemic Lupus Erythematosus (jSLE)

6:00PM-7:00PM

Abstract Number: 153

Double Negative T Cells in Juvenile Dermatomyositis

6:00PM-7:00PM

Abstract Number: 074

Establishment of a Registry for Juvenile Idiopathic Arthritis (JIA) Patients in South Australia (SA): Focus on Patient Reported Outcome Measures (PROMs) and Experiences (PREMs)

6:00PM-7:00PM

Abstract Number: 152

Hemophagocytic Lymphohistiocytosis (HLH) Genetic Variants in Childhood-onset SLE (cSLE) with Macrophage Activation Syndrome (MAS)

6:00PM-7:00PM

Abstract Number: 076

How Do Pediatric Rheumatologists Diagnose Macrophage Activation Syndrome in Systemic Onset Juvenile Idiopathic Arthritis? An Examination of the CARRA Registry

6:00PM-7:00PM

Abstract Number: 173

Impact of a Nutrition-Focused Quality Improvement Intervention on Hospital Readmission Rates in Henoch-Schönlein Purpura with Gastrointestinal Involvement

6:00PM-7:00PM

Abstract Number: 172

Improved Self-efficacy and Knowledge in Pediatric Rheumatology Among General Pediatric Residents Following the Introduction of a Standardized Teaching Series

6:00PM-7:00PM

Abstract Number: 062

Is Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) a Reliable Tool for Detecting Vascular Activity in Treated Childhood-Onset Takayasu’s Arteritis (C-TA)? A Multicenter Study

6:00PM-7:00PM

Abstract Number: 058

Kawasaki Disease in Ontario Children from 1995-2017: A Population-based Descriptive Analysis

6:00PM-7:00PM

Abstract Number: 049

Levels of Anxiety and Depressive Symptoms in Juvenile Idiopathic Arthritis (JIA) and Their Correlation to Disease Manifestations Using Patient-Reported Outcomes Measurement Information System (PROMIS®) Measures

6:00PM-7:00PM

Abstract Number: 050

Long Term Safety of Biologics and Biosimilars in Pediatric Rheumatic Diseases: An Experience from a Single North Indian Centre

6:00PM-7:00PM

Abstract Number: 149

Low C4 Copy Number of Total C4 Gene, C4B Gene and C4BL Gene in Children with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)

6:00PM-7:00PM

Abstract Number: 063

Musculoskeletal Ultrasound Assessment in Pediatric Knee Hypermobility

6:00PM-7:00PM

Abstract Number: 044

Nailing Down Nailfold Capillaroscopy Practices: A Survey of Pediatric Rheumatologists Within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Network

6:00PM-7:00PM

Abstract Number: 052

Nasopharyngeal Pneumococcus Colonization in Patients with Childhood Onset Systemic Lupus Erythematosus (cSLE) Compared to Healthy Controls

6:00PM-7:00PM

Abstract Number: 046

Near Infrared Indocyanine Green Imaging Reveals Altered Anatomy and Diminished Function in Lymphatic Vessels in the Hands of Rheumatoid Arthritis Patients During Flare

6:00PM-7:00PM

Abstract Number: 045

No-Shows: a Search for Modifiable Risk Factors

6:00PM-7:00PM

Abstract Number: 056

Non-criteria Antiphospholipid Antibodies Associated with Pediatric Rheumatic Disease: A Single-Center Case Series

6:00PM-7:00PM

Abstract Number: 048

Novel Algorithm to Increase Sensitivity of Detecting Active Arthritis in Children Through Infrared Thermal Imaging

6:00PM-7:00PM

Abstract Number: 060

Parsing Apart the Pain Experience: Exploring Treatment-Related Pain in Juvenile Idiopathic Arthritis

6:00PM-7:00PM

Abstract Number: 071

Patient Reported Outcomes and Resilience in Pediatric Systemic Lupus Erythematosus

6:00PM-7:00PM

Abstract Number: 047

Patients with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: Clinical Characteristics and Inception Cohorts

6:00PM-7:00PM

Abstract Number: 051

Pediatric Providers’ Perspectives on Suspected Immune-Mediated Diffuse Alveolar Hemorrhage and Clinical Care Pathways

6:00PM-7:00PM

Abstract Number: 061

Perspectives of Radiologist Physicians in the Imaging of Chronic Nonbacterial Osteomyelitis

6:00PM-7:00PM

Abstract Number: 065

Prosthetic Temporomandibular Joint Replacement in a Cohort of Adolescent Patients with Juvenile Idiopathic Arthritis

6:00PM-7:00PM

Abstract Number: 075

Pseudotumor Cerebri Syndrome in Children with Systemic Lupus Erythematosus

6:00PM-7:00PM

Abstract Number: 043

Resolution of Coronary Artery Changes in Patients with Refractory Kawasaki Disease with Prolonged Course of Infliximab: A Case Series

6:00PM-7:00PM

Abstract Number: 067

Response to Treatment with Intra-articular Triamcinolone Hexacetonide and Triamcinolone Acetonide in Oligo-articular Juvenile Idiopathic Arthritis

6:00PM-7:00PM

Abstract Number: 069

Rheumatic Fever in a Tertiary Medical Center – 25 Years of Follow Up

6:00PM-7:00PM

Abstract Number: 042

Safety Analysis of Infliximab-dyyb as Compared to Infliximab in Pediatric Rheumatic Conditions

6:00PM-7:00PM

Abstract Number: 064

The First 18 Months of a Pediatric Rheumatology Service at a Tertiary Referral Hospital in Kenya

6:00PM-7:00PM

Abstract Number: 070

The Importance of the Patient Global Health Assessment of Disease Activity in Polyarticular Juvenile Idiopathic Arthritis

6:00PM-7:00PM

Abstract Number: 150

The Killer Immunoglobulin-like Receptor KIR3DL1 in Combination with HLA-Bw4 Is Associated with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)

6:00PM-7:00PM

Abstract Number: 057

Transition from Pediatric to Adult Rheumatology: The Clinician as a Fundamental Ally

2:30PM-3:00PM

Abstract Number: 006

Increasing Rates of Standardized Depression Screening in Youth with Systemic Lupus Erythematosus in a Pediatric Rheumatology Clinic

2:30PM-3:00PM

Abstract Number: 005

Single Cell Sequencing of the Skin to Define Cell Populations of Interest in Localized Scleroderma (LS)

4:30PM-5:00PM

Abstract Number: 028

A Randomized, Double-blind, Placebo-controlled Study of Anakinra in Pediatric and Adult Patients with Still’s Disease

4:30PM-5:00PM

Abstract Number: 026

Allogeneic Hematopoietic Cell Transplantation (HCT) in the National Institutes of Health (NIH)’s Deficiency of Adenosine Deaminase 2 (DADA2) Patient Cohort

4:30PM-5:00PM

Abstract Number: 039

Assessing Patient Self-Reported Transition Readiness in a Large Pediatric Rheumatology Center

4:30PM-5:00PM

Abstract Number: 038

Change in Treatments and Outcomes After Implementation of a National Diagnosis and Treatment Guarantee Program for Juvenile Idiopathic Arthritis in Chile

4:30PM-5:00PM

Abstract Number: 034

Chest Computed Tomography Manifestations in Childhood-Onset Systemic Lupus Erythematosus: A Single-Center Cohort Study

4:30PM-5:00PM

Abstract Number: 027

Clinical Features and Outcomes in Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature (CANDLE) Syndrome: Before and After JAK-inhibition

4:30PM-5:00PM

Abstract Number: 029

Comparison of Efficacy Between Triamcinolone Acetonide and Hexacetonide Intra-articular Treatment for Clinical Remission in Juvenile Idiopathic Arthritis

4:30PM-5:00PM

Abstract Number: 031

Exome Sequencing for Early Pediatric Systemic Lupus Erythematosus: Standard of Care in 2020?

4:30PM-5:00PM

Abstract Number: 037

Improving Pneumococcal Vaccination Rates in Immunosuppressed Rheumatology Patients

4:30PM-5:00PM

Abstract Number: 036

Medication Related Decision-Making in Parents of Children with Juvenile Idiopathic Arthritis

4:30PM-5:00PM

Abstract Number: 033

Parental Adverse Childhood Experience (ACE) Exposure Is Predictive of Active Lupus in Pediatric Patients

4:30PM-5:00PM

Abstract Number: 040

Patient-Proxy Agreement on Mental Health and Neuropsychological Symptoms Among Youth with Juvenile Fibromyalgia Syndrome

4:30PM-5:00PM

Abstract Number: 035

The Childhood and Rheumatology Research Alliance Systemic Lupus Erythematosus and Related Disorders Cohort

4:30PM-5:00PM

Abstract Number: 030

The Efficacy and Safety of Intraarticular Injection of Triamcinolone Acetonide versus Triamcinolone Hexacetonide in the Treatment of Juvenile Idiopathic Arthritis

4:30PM-5:00PM

Abstract Number: 032

The Impact of Psychiatric Diagnosis and Treatment on Medication Adherence in Youth with Systemic Lupus Erythematosus

5:00PM-6:00PM

Abstract Number: 094

A Good Inter- and Intra-observer Reliability of Subtypes in Nailfold Capillary Micro-haemorrhages in Childhood-onset Systemic Lupus Erythematosus

5:00PM-6:00PM

Abstract Number: 108

A Multinational Study of Thrombotic Microangiopathy in Macrophage Activation Syndrome: A Dreadful Condition Which Is Likely Underrecognized

5:00PM-6:00PM

Abstract Number: 097

A Pilot Randomized Controlled Trial of the iCanCope Pain Self-management Application for Adolescents with Juvenile Idiopathic Arthritis

5:00PM-6:00PM

Abstract Number: 086

Advanced Multidisciplinary Care: A New Approach to Childhood Arthritis

5:00PM-6:00PM

Abstract Number: 082

Anti-Mitochondrial Autoantibodies Are Associated with Dysphagia in Juvenile and Adult Myositis, and with Persistent Weakness and Cardiomyopathy in Adult Myositis

5:00PM-6:00PM

Abstract Number: 175

Application of Juvenile Idiopathic Arthritis Treatment Guidelines and Factors Associated with Increased Likelihood of Intra-articular Corticosteroid Administration

5:00PM-6:00PM

Abstract Number: 089

Associations Among Pain, Mood, and Sleep in Children with Rheumatic Conditions

5:00PM-6:00PM

Abstract Number: 106

Childhood-onset Takayasu Arteritis: A Single Center Case Series of Atypical and Varied Presentations

5:00PM-6:00PM

Abstract Number: 157

Chondrocytes Influence Fibroblast-like Synoviocytes from Patients with Juvenile Idiopathic Arthritis, Through the Abrogation of BMP Signaling, to Delay Cell Differentiation and Maturation

5:00PM-6:00PM

Abstract Number: 110

Consequences and Predictors of Persisting Pain in Children with Juvenile Idiopathic Arthritis: A Case Control Study Nested in the ReACCh-Out Cohort

5:00PM-6:00PM

Abstract Number: 107

Defining the Prevalence of Depression and Anxiety Symptoms in Adolescents with Juvenile Idiopathic Arthritis

5:00PM-6:00PM

Abstract Number: 105

Discovering the Implications of Adiposity in Juvenile Dermatomyositis

5:00PM-6:00PM

Abstract Number: 100

Does Anakinra Dampen Neuronal Damage in Children with Febrile-Infection Related Epilepsy Syndrome (FIRES): A Single Center Review of Neuroimaging

5:00PM-6:00PM

Abstract Number: 098

Early Treatment with Anakinra in Systemic Juvenile Idiopathic Arthritis

5:00PM-6:00PM

Abstract Number: 177

Educational Outcomes in a Young-Adult Cohort of Patients with Childhood Onset Systemic Lupus Erythematosus (SLE)

5:00PM-6:00PM

Abstract Number: 158

Genetics of Age at Diagnosis in Childhood-Onset Systemic Lupus Erythematosus

5:00PM-6:00PM

Abstract Number: 178

HEADSS and Shoulders, Knees and Toes: Improving Sexual Orientation and Gender Identity Screening in the Pediatric Rheumatology Clinic

5:00PM-6:00PM

Abstract Number: 176

Implementation of an Abbreviated Neuropsychology Screening Protocol for Patients Diagnosed with Childhood-onset Systemic Lupus Erythematosus

5:00PM-6:00PM

Abstract Number: 102

Implications of Positive Tests for ANCA in a Pediatric Population

5:00PM-6:00PM

Abstract Number: 174

Improving Hospital Discharge Instructions for Pediatric Rheumatology Patients

5:00PM-6:00PM

Abstract Number: 109

Incidence, Contributing Factors, and Impact of Diagnostic Delay in Juvenile Idiopathic Arthritis: Analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry

5:00PM-6:00PM

Abstract Number: 084

Kawasaki Disease Shock Syndrome: A Single Center Cohort

5:00PM-6:00PM

Abstract Number: 096

Medication Adherence in Adolescents and Young Adults with Childhood Onset SLE

5:00PM-6:00PM

Abstract Number: 156

Metabolic Profiling in Juvenile Dermatomyositis

5:00PM-6:00PM

Abstract Number: 104

Patients Perspectives on Living with a Systemic Autoinflammatory Disease: Impact on Quality of Life

5:00PM-6:00PM

Abstract Number: 155

Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) Is Characterized by a Novel Subset of Monocytes with Markers Associated with Crossing the Blood Brain Barrier (BBB)

5:00PM-6:00PM

Abstract Number: 091

Protracted Febrile Myalgia Findings on Magnetic Resonance Imaging

5:00PM-6:00PM

Abstract Number: 095

Pyoderma Gangrenosum Ulceration as a Presenting Feature of Pediatric Granulomatosis with Polyangiitis (GPA)

5:00PM-6:00PM

Abstract Number: 078

Reliability and Validity of a New Skin Activity Measure for Localized Scleroderma

5:00PM-6:00PM

Abstract Number: 099

Reversible Hepatotoxicity to IL-1/IL-6 Blockade in Pediatric Patients with Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome

5:00PM-6:00PM

Abstract Number: 081

Risk Score of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis

5:00PM-6:00PM

Abstract Number: 087

Standardizing Care and Fostering Systemic Autoinflammatory Disease (SAID) Research Through the CARRA Autoinflammatory Disease Network

5:00PM-6:00PM

Abstract Number: 088

Sun Protection Use in Patients Followed in a Pediatric Rheumatology Clinic in an Urban Setting

5:00PM-6:00PM

Abstract Number: 154

T Helper Cell Differentiation in Polyarticular Juvenile Idiopathic Arthritis

5:00PM-6:00PM

Abstract Number: 092

The Initial Treatment of Systemic Juvenile Idiopathic Arthritis: An International Collaboration Among 10 Registries

5:00PM-6:00PM

Abstract Number: 080

Therapeutic Interferon Gamma Neutralization with Emapalumab in Patients with NRLC4- and CDC42-Associated Diseases Characterized by Recurrent and Severe Hemophagocytic Lymphohistiocytosis

5:00PM-6:00PM

Abstract Number: 079

Traditional Laboratory Parameters and New Biomarkers in Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis

5:00PM-6:00PM

Abstract Number: 093

Treatment of Systemic Juvenile Idiopathic Arthritis in the CARRA Registry

5:00PM-6:00PM

Abstract Number: 077

Tubulointerstitial Nephritis and Uveitis (TINU): A Pediatric Case Series with Longitudinal Followup

5:00PM-6:00PM

Abstract Number: 103

Unexpectedly High Incidence of Kawasaki Disease in a Well-Characterized Population in Atlantic Canada

5:00PM-6:00PM

Abstract Number: 090

Using a Patient-Engaged Approach to Identify Cross-Cutting Disease Factors Impacting Mental Health in Youth with Rheumatologic Disease

5:00PM-6:00PM

Abstract Number: 101

Uveitis Treatment in the CARRA II Registry: Tumor Necrosis Factor-inhibitors and Beyond

5:00PM-6:00PM

Abstract Number: 085

Vitamin C Deficiency: An Under-Recognized Cause for Pediatric Limb Pain

5:00PM-6:00PM

Abstract Number: 111

WITHDRAWN

5:00PM-6:00PM

Abstract Number: 112

WITHDRAWN

5:00PM-6:00PM

Abstract Number: 083

Worsening Disease Activity and Inability to Taper Corticosteroids in an Ethnically Diverse Cohort of Pediatric-Onset Lupus Patients After Transition to Adult Care

11:00AM-12:00PM

Abstract Number: 007

Dense Genotyping of Immunologic Loci Identifies CXCR4 as a Novel Susceptibility Locus for Systemic Juvenile Idiopathic Arthritis

11:00AM-12:00PM

Abstract Number: 009

Emapalumab (Anti-Interferon-Gamma Monoclonal Antibody) in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (sJIA)

11:00AM-12:00PM

Abstract Number: 010

Experience with and Management of HLH-like Toxicities Following Chimeric Antigen Receptor T-Cell Therapy for Treatment of Relapsed/Refractory Pre-B ALL

11:00AM-12:00PM

Abstract Number: 008

Incidence and Risk Factors of Hypogammaglobulinemia and Infectious Complications Associated with Rituximab Use in Pediatric Rheumatic Diseases

4:15PM-5:15PM

Abstract Number: 165

A Massively Parallel Reporter Assay Screen of Genetic Variants on JIA Haplotypes Reveals Variants Associated with Altered Function of an Intergenic Enhancer in the HLA Class II Locus

4:15PM-5:15PM

Abstract Number: 188

A New Multidisciplinary Pediatric SLE Clinic in a Large Urban Care Center: Feasibility, Patient Satisfaction, and Quality After One Year

4:15PM-5:15PM

Abstract Number: 184

A Survey of Uveitis Knowledge Among Juvenile Arthritis Patients and Parents

4:15PM-5:15PM

Abstract Number: 119

Actual Medication Usage of Patients with Juvenile Onset Systemic Lupus Erythematosus Using Japanese Health Insurance Database

4:15PM-5:15PM

Abstract Number: 186

Anthropometric Assessment and Food Intake of Parents of Pediatric Patients with Chronic Rheumatic Diseases

4:15PM-5:15PM

Abstract Number: 145

Anti-Citrullinated Protein Antibodies (ACPA) and Bony Erosions in Polyarticular JIA

4:15PM-5:15PM

Abstract Number: 163

Anti-Dense Fine Speckled (DFS) Autoantibodies in Autoinflammatory Vasculopathies

4:15PM-5:15PM

Abstract Number: 130

Anti-Ro/SSA Is Associated with Progression to End-Stage Renal Disease in Anti-dsDNA Positive Lupus Nephritis

4:15PM-5:15PM

Abstract Number: 115

Carbohydrate and Sugar Intake Predict Pain in Teens with Active JIA Disease but Not in Teens in Remission or Controls: A Cross-Sectional, Case-Control Metabolomics Pilot Study

4:15PM-5:15PM

Abstract Number: 160

CD3 Downregulation on T-cells Is Concomitant with Arginase Upregulation on Myeloid Cells in Synovial Fluid of Patients with Juvenile Idiopathic Arthritis

4:15PM-5:15PM

Abstract Number: 120

Characteristics of the New Childhood Arthritis and Rheumatology Research Alliance Registry of Juvenile Myositis Patients Enrolled in the First Two Years

4:15PM-5:15PM

Abstract Number: 148

Chronic Fatigue Symptoms in Children with Abrupt Early-onset OCD And/or PANS

4:15PM-5:15PM

Abstract Number: 132

Clinical Characteristics and Outcomes of Critically Ill Children Requiring Rheumatology Consultation in a Large Intensive Care Unit

4:15PM-5:15PM

Abstract Number: 183

Collaboration Between Rheumatology Clinic and Specialty Pharmacy to Positively Impact Patient Experience and Hospital Stewardship

4:15PM-5:15PM

Abstract Number: 126

Cyclophosphamide as Rescue Therapy for Kawasaki Disease with Peripheral Vascular Disease: A Single Center Experience

4:15PM-5:15PM

Abstract Number: 141

Cyclophosphamide Use in Treatment of Refractory Kawasaki Disease: A Single Center Case Series of 10 Patients and Literature Review

4:15PM-5:15PM

Abstract Number: 127

Disease Characteristics and Medication Utilization in Lupus Nephritis Associated with Childhood-Onset Systemic Lupus Erythematosus

4:15PM-5:15PM

Abstract Number: 121

Evaluating the Relationship Between Juvenile Idiopathic Arthritis Disease Activity and Uveitis Activity: A Retrospective Analysis

4:15PM-5:15PM

Abstract Number: 113

Evaluation of B-cell Depletion with Rituximab and IVIG Concurrent Treatment in Pediatric Autoimmune Brain Disease

4:15PM-5:15PM

Abstract Number: 134

Evaluation of Self-report Screening Measures in the Detection of Depressive and Anxiety Disorders Among Children and Adolescents with Systemic Lupus Erythematosus

4:15PM-5:15PM

Abstract Number: 193

Examining Social Loafing and the Free-Rider Effect in Transition Readiness Among Youth with jSLE

4:15PM-5:15PM

Abstract Number: 168

Examining the Role of IFN-I and Langerhans Cell ADAM17 in Lupus Photosensitivity

4:15PM-5:15PM

Abstract Number: 144

Failure of Methotrexate Monotherapy and Subsequent Response to Tumor Necrosis Factor Inhibitors in Pediatric Non-Infectious Uveitis

4:15PM-5:15PM

Abstract Number: 147

Familial Clustering of Immune-mediated Diseases in Children with Abrupt-onset OCD

4:15PM-5:15PM

Abstract Number: 117

Family Impact of Juvenile Localized Scleroderma

4:15PM-5:15PM

Abstract Number: 125

Feasibility and Pilot Study of Mental Health Screening in Juvenile Myositis

4:15PM-5:15PM

Abstract Number: 181

Health Care Professionals and Transition to Adulthood for Youth with Juvenile Idiopathic Arthritis

4:15PM-5:15PM

Abstract Number: 146

Immersive Virtual Reality for Management of Amplified Musculoskeletal Pain Syndrome in Adolescents: A Pilot Randomized Controlled Trial

4:15PM-5:15PM

Abstract Number: 143

Immunological Profiles Following Treatment with Rituximab in Autoimmune Disease

4:15PM-5:15PM

Abstract Number: 161

Impact of the Month of Birth on the Development of Juvenile Idiopathic Arthritis in the United States

4:15PM-5:15PM

Abstract Number: 189

Influenza Immunization: A Quality Assurance Survey in a Pediatric Rheumatology Clinic

4:15PM-5:15PM

Abstract Number: 180

Influenza Knowledge and Barriers to Vaccination in Immunosuppressed Patients in the Pediatric Rheumatology Clinic

4:15PM-5:15PM

Abstract Number: 159

Interleukin-18 as a Key Cytokine to Understand Pathology and to Decide Appropriate Therapeutic Strategy in Chronic Arthritic Systemic Juvenile Idiopathic Arthritis

4:15PM-5:15PM

Abstract Number: 123

Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Those with Sacroiliitis

4:15PM-5:15PM

Abstract Number: 167

Lipidomic Profiles of Synovial Fluid from Patients with Oligoarticular Juvenile Idiopathic Arthritis Naïve to Treatment

4:15PM-5:15PM

Abstract Number: 118

Long-Term Outcomes in Children Born to Anti-Ro and/or anti-La Positive Mothers

4:15PM-5:15PM

Abstract Number: 137

Measuring Decision Conflict in Parents of Children with Juvenile Idiopathic Arthritis When Making the Decision to Begin Disease Modifying Anti-Rheumatic Drugs or Biologic Agents

4:15PM-5:15PM

Abstract Number: 162

Minor Biomarkers in Juvenile Idiopathic Arthritis (JIA)

4:15PM-5:15PM

Abstract Number: 114

Musculoskeletal Ultrasound Study in Childhood Arthritis: A Limited Examination

4:15PM-5:15PM

Abstract Number: 182

Needs of Youth with Juvenile Idiopathic Arthritis During the Transition to Adulthood

4:15PM-5:15PM

Abstract Number: 179

New Juvenile Idiopathic Arthritis Quality Measure Set for the Pediatric Rheumatology Care and Outcomes Improvement Network

4:15PM-5:15PM

Abstract Number: 139

Ongoing Disease Activity in Juvenile Idiopathic Arthritis (JIA) 18 Years After Disease Onset: A Population-based Nordic Study

4:15PM-5:15PM

Abstract Number: 190

Outcomes of an Evidence Based Guideline for the Treatment of Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome

4:15PM-5:15PM

Abstract Number: 116

Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry

4:15PM-5:15PM

Abstract Number: 133

Pediatric Rheumatology Consultation for Both Traditional and Emerging Rheumatic Diseases in the Critical Care Setting

4:15PM-5:15PM

Abstract Number: 187

Perspectives of Adolescents and Young Adults Around Implementing Rheumatology Healthcare Transition: Preliminary Qualitative Findings

4:15PM-5:15PM

Abstract Number: 185

pGALS Training Increases Canadian and Kenyan Physicians’ Confidence in Examining the Musculoskeletal System in Children

4:15PM-5:15PM

Abstract Number: 124

Pharmacist Role in an Outpatient Adolescent Complex Pediatric Lupus Clinic

4:15PM-5:15PM

Abstract Number: 131

Practice Patterns for Consulting Pediatric Rheumatology in a Large Pediatric Intensive Care Unit

4:15PM-5:15PM

Abstract Number: 128

Predictors of Moderate/High Disease Activity in Childhood-Onset Systemic Lupus Erythematosus

4:15PM-5:15PM

Abstract Number: 136

Prevalence of Paradoxical Psoriasis After Exposure to Tumor Necrosis Factor Inhibitors (TNFi) in Children from a Single Tertiary Center

4:15PM-5:15PM

Abstract Number: 129

Reproductive Health Concerns in Young Adults with Pediatric Onset Rheumatic Diseases

4:15PM-5:15PM

Abstract Number: 166

Resident Memory T Cells in Human RA Synovium Display Restricted TCR Clones

4:15PM-5:15PM

Abstract Number: 138

Serious Infection Risk in Pediatric Patients with Low Immunoglobulin Levels Following Rituximab Treatment for Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)

4:15PM-5:15PM

Abstract Number: 140

Serum Biomarkers in a German Cohort of Patients with Systemic Juvenile Idiopathic Arthritis and Their Relationship to Response to Interleukin-1 Blockade

4:15PM-5:15PM

Abstract Number: 192

Single Center Consensus of Prophylactic Treatment in Immunocompromised Children with Rheumatic Disease

4:15PM-5:15PM

Abstract Number: 122

Systemic Inflammation and Cognitive Dysfunction in jSLE Patients

4:15PM-5:15PM

Abstract Number: 164

The Juvenile Idiopathic Arthritis-Associated IL2RA and IL6R Haplotypes Contain Enhancers Whose Functions Are Altered by JIA-Associated Genetic Variants

4:15PM-5:15PM

Abstract Number: 135

Use of Intravenous Pamidronate in Pediatric Leukemia Patients with Osteonecrosis Results in Reduced Pain and May Halt Osteonecrosis Progression

4:15PM-5:15PM

Abstract Number: 191

Utilization of Telemedicine in Pediatric Rheumatologic Care

4:15PM-5:15PM

Abstract Number: 142

WITHDRAWN